Maybe not being more critical has been the main problem? Leo continues to brush off the financials when asked, but has no solution... His strategy "3 years ago" was non-partnership, dilute the shares and build 3 drugs past phase 3. What has not happened is stock appreciation to offset Aspire's continued onslaught. So now, Leo is fully dependable on partnership/sale to survive. Time is running out on the 11 year "next Regeneron" dream...